Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.

Roberson PL, Wilderman SJ, Avram AM, Kaminski MS, Schipper MJ, Dewaraja YK.

Cancer Biother Radiopharm. 2014 Feb;29(1):26-33. doi: 10.1089/cbr.2012.1467.

2.

Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma.

Roberson PL, Amro H, Wilderman SJ, Avram AM, Kaminski MS, Schipper MJ, Dewaraja YK.

Eur J Nucl Med Mol Imaging. 2011 May;38(5):874-83. doi: 10.1007/s00259-010-1699-3.

3.

Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.

Koral KF, Dewaraja Y, Li J, Barrett CL, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

J Nucl Med. 2000 Sep;41(9):1579-86.

4.

Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD.

J Nucl Med. 2003 Feb;44(2):260-8.

5.
6.

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, Youssef E, Regan D, Wilderman SJ, Roberson PL, Kaminski MS, Avram AM.

J Nucl Med. 2014 Jul;55(7):1047-53. doi: 10.2967/jnumed.113.136044.

7.

Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.

Schipper MJ, Koral KF, Avram AM, Kaminski MS, Dewaraja YK.

Cancer Biother Radiopharm. 2012 Sep;27(7):403-11. doi: 10.1089/cbr.2011.1053.

8.

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, Koral KF, Kaminski MS, Avram AM.

J Nucl Med. 2010 Jul;51(7):1155-62. doi: 10.2967/jnumed.110.075176.

9.

Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.

Boucek JA, Turner JH.

Cancer Biother Radiopharm. 2014 Feb;29(1):18-25. doi: 10.1089/cbr.2013.1490.

PMID:
24134141
10.

Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculations.

Howard DM, Kearfott KJ, Wilderman SJ, Dewaraja YK.

Cancer Biother Radiopharm. 2011 Oct;26(5):615-21. doi: 10.1089/cbr.2011.0965.

11.

Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.

Koral KF, Dewaraja Y, Li J, Lin Q, Regan DD, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

J Nucl Med. 2003 Mar;44(3):457-64.

13.

Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report.

Koral KF, Dewaraja Y, Clarke LA, Li J, Zasadny KR, Rommelfanger SG, Francis IR, Kaminski MS, Wahl RL.

Cancer Biother Radiopharm. 2000 Aug;15(4):347-55.

PMID:
11041019
14.

Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients.

Koral KF, Kaminski MS, Wahl RL.

J Nucl Med. 2003 Sep;44(9):1541-3; author reply 1543. No abstract available.

15.

Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.

Hartmann Siantar CL, DeNardo GL, DeNardo SJ.

J Nucl Med. 2003 Aug;44(8):1322-9.

16.

Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Dewaraja YK, Wilderman SJ, Koral KF, Kaminski MS, Avram AM.

Cancer Biother Radiopharm. 2009 Aug;24(4):417-26. doi: 10.1089/cbr.2008.0568.

17.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.

J Nucl Med. 2003 Dec;44(12):2000-18.

18.

Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.

Hobbs RF, Wahl RL, Frey EC, Kasamon Y, Song H, Huang P, Jones RJ, Sgouros G.

J Nucl Med. 2013 Sep;54(9):1535-42. doi: 10.2967/jnumed.112.117952.

19.
20.

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW.

J Nucl Med. 2008 May;49(5):837-44. doi: 10.2967/jnumed.107.043190.

Supplemental Content

Support Center